阿根廷队列中Gam-COVID-Vac疫苗诱导的中和反应及针对SARS-CoV-2 P.1变异株的评价
在285名阿根廷参与者中评估Sputnik-V疫苗的体液免疫反应与安全性,接种后42天99.65%个体有抗S IgG,但23.15%未检出中和抗体;对野生型的中和效力显著高于P.1变异株(p<0.001);从一名完成两剂接种者鼻咽拭子中139天后分离出活P.1病毒。
要点
- 接种后42天99.65%个体产生抗S IgG,但23.15%未检出中和抗体。
- 对野生型的中和效力显著高于P.1变异株(p<0.001)。
- 从完成两剂接种者鼻咽拭子中139天后分离出活P.1病毒。
核心结论
- Sputnik-V疫苗安全并诱导有效的体液免疫反应,但并非所有免疫个体都产生中和抗体。
- 疫苗可能避免COVID-19重症,但不预防感染,也不阻止完全接种者的传播。
研究设计与样本
- 在阿根廷队列中招募285名参与者,于接种前、接种后14天和42天检测抗S IgG抗体和中和抗体。
- 同时评估接种者的安全性和疾病发生率,并检测疫苗诱导及感染诱导的中和抗体对P.1变异株的活性。
主要发现
- 所有参与者报告耐受良好,未发生任何严重不良事件。
- 完全接种者中确认9例COVID-19病例,并从其中1例成功分离出活P.1变异株。
- 接种后42天,99.65%个体有抗S IgG,23.15%未检出中和抗体。
- 对野生型的中和效力显著高于P.1(p<0.001)。
- 部分样本未能中和P.1,主要见于未感染过疫苗的受试者;既往感染后接种者中未观察到显著差异。
临床怎么用
- 作者认为疫苗可能避免COVID-19重症,但不预防感染,也不阻止完全接种者的传播。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated humoral immune-response elicited by Sputnik-V by measuring anti-Spike (S) IgG antibodies (Abs) and neutralizing antibodies (NAb) prior to, 14 and 42 days after-vaccination. The safety and disease rates among vaccinated individuals were also evaluated. Since SARS-CoV-2 lineage P.1 is rapidly spreading in Argentina, virus-neutralizing activity of Sputnik-V-elicited and infection-elicited NAb faced to P.1 were also assessed. A total of 285 participants were recruited; all reported good tolerance, without any severe adverse event. Nine COVID-19 cases were confirmed in fully vaccinated individuals and viable P.1 variant was successfully isolated from one of them. At day 42, 99.65% of the individuals had anti-S IgG; however, 23.15% had not detectable NAbs. Significantly higher neutralization potency against WT compared to P.1 (p < 0·001) was observed. Some samples failed to neutralize P.1, mainly among vaccinated-naїve subjects; however, no significant differences were observed among previously infected-vaccinated individuals. Our results corroborated that Sputnik-V is safe and induces an efficient humoral immune response, although not all immunized subjects develop Nabs. Herein, we show for the first time, evidence of infectious SARS-CoV-2 shedding from Sputnik-V fully vaccinated individuals, by the isolation of viable virus from the nasopharyngeal swab of one participant of our study, 139 days after receiving the second dose. Thereby, we provide evidence indicating that the vaccine might avoid severe forms of COVID-19 but does not prevent infection nor prevents transmission from a fully vaccinated individual.
引用
- Blanco S, Salomé Konigheim B, Diaz A, et al. Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. Vaccine. 2021. PMID: 34953609. doi:10.1016/j.vaccine.2021.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。